A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031230019

Enrollment

200

Registered

2023-04-13

Start date

2023-04-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Myasthenia Gravis

Interventions

ALXN1720 or Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Diagnosis of MG with generalized muscle weakness meeting the clinical criteria defined by Myasthenia Gravis Foundation of America (MGFA) Class II, III or IV - Positive serological test for autoantibodies against AChR.

Exclusion criteria

Exclusion criteria: - History of thymectomy or any other thymic surgery within 12 months prior to Screening - Untreated thymic malignancy, carcinoma, or thymoma - History of Neisseria meningitidis infection - Pregnancy, breastfeeding, or intention to conceive during the course of the study.

Design outcomes

Primary

Measure	Time frame
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score at Week 26	—

Secondary

Measure	Time frame
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Total Score at Week 26	—

Countries

Japan, Spain, US

Contacts

Public ContactMichinori Terada

Alexion Pharma GK

JPDept-DevOps-PMCO@alexion.com+81-3-3457-9559

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026